Connect with us

News

Laurentian Bank Securities Inc. Initiates Analyst Coverage of Liberty Defense and Technology Transfer Award

StockPrice

Published

on

TSXV: SCAN 
Frankfurt : LD2     
OTCQB: LDDFF

VANCOUVER , Sept. 10, 2019 /CNW/ – Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN; FRANKFURT : LD2; OTCQB:LDDFF), a leading concealed weapons detection solutions company, is pleased to announce that Laurentian Bank Securities Inc. has initiated coverage of the Company, that MIT has received the FLC Award for its transfer of the technology behind HEXWAVE, and the Company’s recent presentation to the National Legislative Service and Security Association (NLSSA).

Liberty Defense Holdings Ltd. (CNW Group/Liberty Defense Holdings Ltd.)
Liberty Defense Holdings Ltd. (CNW Group/Liberty Defense Holdings Ltd.)

Analyst Coverage

Laurentian Bank Securities Inc. is a subsidiary of Laurentian Bank of Canada . Established in Montreal in 1846, Laurentian Bank of Canada is a fully integrated financial services provider with operations throughout Canada .

REPORT – Breakthroughs In Technology Put A Direct Target On 1 Weapons Detection Stock

The initiation research report, dated September 10, 2019 , was written and produced by Laurentian Bank Securities Inc.’s Managing Director and Head of Research, Nick Agostino , CFA, MBA, P.Eng., as an independent analysis of Liberty’s activities and progress. Since 2000, Nick has specialized in equity research.

A full copy of this report is available upon request from a Laurentian Bank Securities Inc. representative.

MIT Technology Transfer Award

MIT LL has been notified that it will receive the Excellence in Technology Transfer award from the Federal Laboratory Consortium (“FLC”) for developing the microwave imaging system used in Liberty’s HEXWAVE weapon detection system. This real time 3D imaging technology can operate at a video rate (~10 Hz), to screen a constant flow of subjects and minimize traffic flow obstruction. This revolutionary technology has the potential to change the face of security technology, allowing for more functional safety features for spaces within the global urban security environment. FLC research and development fosters scientific and technological breakthroughs that ultimately work to benefit the country’s economy.

“It is an honour to be part of bringing a new wave of security capability to the global urban security market and seeing the technology behind it recognized is quite inspiring and a well-deserved tribute to the cooperative energy and innovative leadership of the development teams,” said Bill Riker , Liberty Defense CEO. “We intend to use the real time 3D imaging system developed by MIT LL to its full capacity, by pairing it with HEXWAVE’s other subsystems.  

NLSSA Presentation

Recently, Bill Riker and COO and US President Aman Bhardwaj were invited to present a briefing on HEXWAVE’s 3D active threat detection technology at the annual training conference of the National Legislative Service and Security Association (NLSSA) summer meeting in Tallahassee, Florida . The NLSSA is a group committed to the professional development of career legislative and security professionals, including the Sergeants-at-Arms from the 50 US State Capitals. This association is integral to the mission of securing the capitals in all 50 states. 

 “We are pleased to have had Liberty Defense present at our most recent NLSSA Training Conference to provide our Association’s Security Professionals with a technical product briefing on HEXWAVE. The product’s cutting edge screening capability holds exceptional promise for the industry and we look forward to continued opportunities to evaluate HEXWAVE in our respective state capitols. Liberty Defense’s next-generation system may become the means by which we secure many important facilities in the future,” said NLSSA President Chief Martin Brock, Chief of the North Carolina General Assembly Police Department.”

The audience included Florida Senate President Bill Galvano and many state capital security professionals who expressed interest in the HEXWAVE technology.

NLSSA is a part of the National Conference of State Legislatures (NCSL), a bi-partisan organization committed to the sharing of best practices to promote good policy across the United States and its 50 state legislative bodies. The NCSL Summit, held most recently in Nashville , attracted almost 8,000 registrants, and of those, more than 3,000 were legislators from state house and senate chambers from all 50 states and the territories.

On Behalf of Liberty Defense 
Bill Riker 
CEO & Director

About Liberty Defense 
Liberty provides security solutions for concealed weapon detection in high volume foot traffic areas and has secured an exclusive license from Massachusetts Institute of Technology ( MIT ), as well as a technology transfer agreement, for patents related to active 3D radar imaging technology that are packaged into the HEXWAVE product. The system is designed to provide discrete, modular and scalable protection to provide layered, stand-off detection capability. This is intended to provide a means to proactively counter evolving urban threats. The sensors with active 3D radar imaging and Artificial Intelligence (AI)-enhanced automatic detection are designed to detect metallic and non-metallic firearms, knives, explosives and other threats. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense.com

About Laurentian Bank of Canada 
The Laurentian Bank of Canada is a financial institution founded in 1846 that operates throughout Canada . The Bank caters to the needs of retail clients via its branch network based in Quebec . The Bank also stands out for its know-how among small and medium-sized enterprises and real estate developers owing to its specialized teams across Canada . Its subsidiary B2B Bank is, for its part, one of the major Canadian leaders in providing banking products and services and investment accounts through independent advisors and brokers. Laurentian Bank Securities offers integrated brokerage services to a clientele of institutional and retail investors.

About the Federal Laboratory Consortium for Technology Transfer
The Federal Laboratory Consortium for Technology Transfer is the formally chartered, nationwide network of over 300 federal laboratories, agencies, and research centers that fosters commercialization best practice strategies and opportunities for accelerating federal technologies from out of the labs and into the marketplace.

FORWARD-LOOKING STATEMENTS

When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of their respective officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. The forward-looking statements and information in this press release include, amongst others, information relating to initiating coverage, MIT’s Excellence in Technology Transfer award, and NCSL. Such statements and information reflect the current view of Liberty. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: (a) there may be no future analyst coverage reports, (b) the Company may not be involved in any future awards, and (c) the Company may not participate in any future national conferences. These fluctuations may adversely affect the price of the Liberty’s securities, regardless of its operating performance. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: currency fluctuations; limited business history of the parties; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. The parties undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of their securities or their respective financial or operating results (as applicable).

Liberty caution that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of the parties as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

All amounts referred to herein are in Canadian dollars unless otherwise indicated.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Liberty Defense Holdings Ltd.

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For previous compensation see our FULL DISCLAIMER HERE

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/10/c4575.html

Continue Reading
Click to comment

News

SNAP Stock Price Surging Big In 2019, Here Are Key Drivers

Joe Samuel

Published

on

Snap Inc (SNAP Stock Report) has had an exceptional 2019 and has seen its stock gain 190% year-to-date. Snap continues to perfume well and has outpaced the growth of peers such as Twitter and Facebook.

Evan Spiegel, the CEO of the company, has been selling millions of Snap’s stock, and last week he sold stock worth more than $33 million. It seems this is the trend currently as both Amazon CEO, Jeff Bezos, and Facebook CEO, Mark Zuckerberg, have also been selling shares of their companies.

[Read More] Airline Stocks In Focus; Spur Interest In Detection Tech Companies?

After a torrid 2018, fundamentals of Snap are slowly improving and uses base has continued to grow steadily. Here are things to consider if the stock is worth buying.

Improving User Base Growth

Last year the company’s user base struggled, but things have changed this year. In the first quarter, the company added 4 million daily active users, and in the second quarter, the company grew users to 13 million.

Currently, the company boasts 500 million active users, and this is a result of the company’s updated version of its app and more focus on AR technology. Recently the company said it would partner with Spotify to allow users to share podcasts and music directly in the app.

Avoiding Regulatory Issues

This year the company has managed to avoid much of the criticism it endured last year with top executives leaving. It has also avoided regulatory issues that tech companies such as Facebook have faced in recent times. For instance, Facebook has faced criticism over its cryptocurrency project Libra and recently FTC fined Facebook $5 billion.

Introduction of Gaming

Although the company’s advertising business is doing well, they are nonetheless focusing on gaming business as a new source of revenue. In April, Snap launched Snap Games which caught the attention of Zynga which introduced a new battle royale game on the platform. Gaming could bring the company millions in sales revenue in 2020.

The company’s Q3 revenue guidance shows that the company expects revenue to range from $410 million to $435 million.

Continue Reading

Featured

Airline Stocks In Focus; Spur Interest In Detection Tech Companies?

Joe Samuel

Published

on

defense stocks to buy

Airline stocks are in focus as Crude Oil Posts the Biggest One Day Gains on Saudi Attack

Any disruption to the oil production industry in Saudi Arabia can lead to utter chaos in a different industry. But some industries are more affected than others and one of those in the aviation industry. As everyone knows, the drone attacks on the Saudi Arabian oil facilities Saturday have knocked out a large chunk of the world’s oil supply. That had a major effect on aviation stocks in the short term.

Fuel costs are the biggest cost for most airlines and once the price of oil going through the rook, the shares of American Airlines Group Inc (NASDAQ:AAL) declined significantly as well. On Monday, the stock fell by as much as 7% to close at $27.77. But this mixe of attacks and focus on airlines could have a different impact on sectors like weapons detection & defense.

Defense Stocks In Focus

There have been more mass shootings this year in the United States than there have been days in the year. Over 330 mass shootings [1], to be exact. This is becoming a huge issue that is costing precious lives and could see billions of dollars spent to fix this situation. Furthermore, airports across the world are working hard to prevent potentially devastating attacks on a daily basis. But the technology could be dramatically flawed.

Global spending on security solutions is projected to reach $7.4 billion in 2019 and increase to over $11.3 billion by 2025 with a CAGR of 8.2%.  The urban Security explosives and Weapons Detection market is slated to grow to nearly $7.5 billion by 2025 and is forecast to see consistent growth for the next several years [2].

What does this mean? Well, for investors it could signal big opportunities but with so many large companies targeting surveillance systems and weapon detection devices as a “go-to,” is there anything that could truly disrupt this market?

Liberty Defense (SCAN.V) (LDDFF) Is Positioning To Change The Face Of Threat Detection For Good

The truth of the matter is that mass shootings now happen more than once a day in the US and as we’ve come to find, there’s no real way to stop these attacks after an attacker enters a space. This is where the real opportunity is: stopping an attack before someone even enters a vulnerable space.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) plans to do that using HEXWAVE, a next-generation high-tech security scanning system that will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively. The demand is present and Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) has already inked several Memorandums of Understanding for beta testing of HEXWAVE, which is expected to start in early 2020.

New Uptrend: Since hitting lows of C$0.56 last week, Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) has seen price and volume increase as well. This week the market has already hit highs of C$0.70.

High Impact on Airline Stocks

Getting back to airline stocks, the drone attack knocked off as many as 5.5 million barrels of oil but today Saudi news stated that it expects to recover quicker than initially expected. Saudi Arabia is one of the biggest oil suppliers to the United States.

So, it wasn’t a surprise that stocks of airlines in America were the hardest hit by this selloff. Today, however, airline stocks are back flying. While United Airlines Holdings Inc (NASDAQ:UAL) and Delta Air Lines, Inc. (NYSE:DAL) lost 3% and 1.50% respectively, it was American Airlines Group that led the decline. Today, all three are up considerably.

Continue Reading

Biotechnology

PharmaCyte Biotech (PMCB) Provides Information on Upcoming Shareholder Update Call

Joe Samuel

Published

on

biotech stock price

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided the call information for PharmaCyte’s upcoming shareholder update call on September 20, 2019.

The call is scheduled for Friday, September 20, 2019, commencing at 4:00 p.m. Eastern Daylight Time. The telephone number for the call is (515) 604-9056. The access code for the call is 195-864.

The call is designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to treat locally advanced, inoperable pancreatic cancer and developments related to PharmaCyte’s product pipeline on which PharmaCyte has been working and that have not yet been reported in a press release.

Questions may be submitted to PharmaCyte for the CEO to answer in a Q&A session following the update. Questions must be submitted in writing to investorrelations@pharmacyte.com by the close of business on Wednesday, September 18, 2019.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is developing the use of genetically modified liver cells and stem cells, as well as beta islet cells, to treat diabetes. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte, including statements regarding the timing and commencement of our first Phase 2b clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise

More information about PharmaCyte can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005309/en/

Contact:Dr. Gerald W. Crabtree
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com